![](/images/graphics-bg.png)
Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation andor Conventional Chemotherapy: Report of a Case
Joint Authors
Soverini, S.
De Benedittis, C.
Bucelli, Cristina
Cattaneo, Daniele
Ferla, Valeria
Zappa, Manuela
Iurlo, Alessandra
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-08-14
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Currently, imatinib and dasatinib are the only tyrosine-kinase inhibitors approved in the US and Europe for the treatment of blast crisis of chronic myeloid leukemia (BC-CML) at diagnosis, while ponatinib is the only inhibitor used in patients bearing T315I mutation.
Here we report the case of a 61-year-old man diagnosed with B-cell lymphoid BC-CML, initially treated with imatinib 800 mg day and then with dasatinib 140 mg day because of intolerance.
A complete cytogenetic response (CCyR) was achieved at three months; however, three months later a relapse was observed, and the T315I mutation was detected.
Ponatinib 45 mg once daily was then started together with a short course of chemotherapy.
Bone marrow evaluation after six months of therapy showed the regaining of CCyR, together with the achievement of a deep molecular response.
However, one year from ponatinib start the patient experienced a new disease relapse; he was effectively treated with ponatinib and chemotherapy once again, but in the meanwhile an ischemic stroke was detected.
This case report confirms the high efficacy of ponatinib monotherapy in BC-CML patients, representing a valid option for non-allogeneic stem cells transplantation eligible cases and the only one available for those carrying the T315I mutation.
American Psychological Association (APA)
Bucelli, Cristina& Cattaneo, Daniele& Ferla, Valeria& Zappa, Manuela& De Benedittis, C.& Soverini, S.…[et al.]. 2017. Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation andor Conventional Chemotherapy: Report of a Case. Case Reports in Hematology،Vol. 2017, no. 2017, pp.1-5.
https://search.emarefa.net/detail/BIM-1145919
Modern Language Association (MLA)
Bucelli, Cristina…[et al.]. Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation andor Conventional Chemotherapy: Report of a Case. Case Reports in Hematology No. 2017 (2017), pp.1-5.
https://search.emarefa.net/detail/BIM-1145919
American Medical Association (AMA)
Bucelli, Cristina& Cattaneo, Daniele& Ferla, Valeria& Zappa, Manuela& De Benedittis, C.& Soverini, S.…[et al.]. Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation andor Conventional Chemotherapy: Report of a Case. Case Reports in Hematology. 2017. Vol. 2017, no. 2017, pp.1-5.
https://search.emarefa.net/detail/BIM-1145919
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1145919